>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Favipiravir 法匹拉韦; T-705

Favipiravir (T-705) 是一种病毒 RNA 聚合酶 (RNA polymerase) 抑制剂，可转变为其活性形式 Favipiravir-ribofuranosyl-5′-triphosphate (RTP)。Favipiravir-RTP 抑制流感病毒RNA依赖性的RNA聚合酶 (RdRP) 活性，IC50 为 341 nM。

货号：
TK0247
规格：

5mg

10mg
价格：
￥0.00

产品参数

CAS No.	259793-96-9
生物活性	Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC50 of 341 nM.
分子式	C5H4FN3O2
分子量	157.1
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	Powder -20°C 3 years
溶解性数据	DMSO : ≥ 100 mg/mL (636.54 mM) H2O : 6.25 mg/mL (39.78 mM; Need ultrasonic)
体内研究	Favipiravir (T 705) (30 mg/kg/day, orally) improves survival compare to placebo. Favipiravir (T 705) also provides significant protection against the A/Duck/MN/1525/81(H5N1) virus at a dose of 33 mg/kg/day or more, regardless of the number of daily doses. When given 4 times a day, all mice survive.
体外研究	Favipiravir (T 705) is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. Favipiravir (T 705) is a novel antiviral compound that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRP) of influenza and many other RNA viruses. Favipiravir-RTP does not inhibit the human DNA polymerase α, β or γ with IC50>1 mM. The IC50 for the human RNA polymerase II is 905 μM; Favipiravir is therefore 2,650 times more selective for the influenza virus RdRP, consistent with the lack of inhibition of host-cell DNA and RNA synthesis. Favipiravir (T 705) acts as a pro-drug, its cytotoxicity is expected to be cell-line dependent. Favipiravir inhibits in a dose-dependent manner MNV-induced CPE (EC50: 250±11 μM) and MNV RNA synthesis in cell culture (EC50:124±42 μM). Despite this rather modest antiviral activity, Favipiravir (T 705) is able to completely inhibit norovirus replication at a concentration of 100 μg/mL, which is a concentration that has little or no adverse effect on the host cell (cell viability >80%).
文献	•Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. •Bioeng Transl Med. 2020 Dec 1;6(1):e10196. •Int J Biol Sci. 2020 Oct 16;16(16):3100-3115. •Antiviral Res. 2020 Dec;184:104955. •Antiviral Res. 2018 Jan;149:34-40. •Front Pharmacol. 2019 Oct 16;10:1203. •Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00222-20. •Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00003-19. •J Virol. 2021 Jul 21;JVI0092221. •Viruses. 2021, 13(10), 2047. •Viruses. 2021 Jun 28;13(7):1255. •Viruses. 2020 Jun 10;12(6):628. •Viruses. 2018 Aug 16;10(8). pii: E433. •Sci Rep. 2021 Sep 8;11(1):17810. •Antivir Res. 2020 Jun;178:104786. •Vaccine. 2019 Aug 2;37(33):4686-4693. •Virology. 2020 Jun;545:1-9. •Virology. 2019 Oct;536:58-67. •J Infect Chemother. 19 October 2021. •J Virol Methods. 2021 Sep 14;298:114283. •BMC Vet Res. 2019 Sep 2;15(1):316. •Biopharm Drug Dispos. 2021 Mar 22. •J Anal Sci Technol. 2021 Feb 19. •Research Square Preprint. 2021 Oct. •Research Square Preprint. 2021 Apr. •Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep. •bioRxiv. 2020 Apr.
纯度及产品资料	98%

推荐产品